Purpose: Paclitaxel is used worldwide in the treatment of breast, lung, ovarian, and other cancers. Sensory peripheral neuropathy is an associated adverse effect that cannot be predicted, prevented, or mitigated. To better understand the contribution of germline genetic variation to paclitaxel-induced peripheral neuropathy, we undertook an integrative approach that combines genome-wide association study (GWAS) data generated from HapMap lymphoblastoid cell lines (LCL) and Asian patients.
Introduction
Paclitaxel, a microtubule-stabilizing agent that binds tubulin and disrupts cell division, represents standard of care for common cancers, including breast, lung, and ovarian cancer (1). Unfortunately, about 20% to 30% of patients treated with paclitaxel experience clinically relevant sensory peripheral neuropathy (2, 3) . Furthermore, there is substantial interpatient variability in time to symptom onset, time to peak symptoms, severity of peak symptoms, and reversibility (4, 5) . Patients experiencing moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) report a reduced quality of life, chronic discomfort, and disruption of physical abilities for general life activities that can be temporary or permanent (6) . CIPN causes a significant symptom burden because many patients that undergo adjuvant treatment are long-term survivors. Moreover, CIPN can lead to dose reduction of the chemotherapeutic agent or possible cessation of treatment (7) . This may have an adverse impact on cancer treatment and disease outcomes, particularly in the adjuvant setting.
There are few effective methods in clinical practice for managing peripheral neuropathy. ASCO recommendations, recently published (7) and based on a systematic evaluation of 48 randomized controlled trials, concluded that there are no agents recommended for the prevention of CIPN and supported a moderate recommendation of duloxetine for pain associated with CIPN (8) . Physical therapy, acupuncture, massage, and medications such as steroids, antiepileptics, antidepressants, and opioids for pain management are often attempted. Unfortunately, the extent to which these interventions improve symptoms is limited and some of these interventions carry side effects of their own (7) . An improved understanding of the genetic variants and genes contributing to paclitaxel induced neuropathy will assist in the development of future neuroprotective agents and in the design of novel therapies with improved toxicity profiles. Furthermore, finding predictive genetic biomarkers could enable identification of patients who should be treated with neuroprotective agents (when they are available) and/or be treated with reduced paclitaxel doses or switched to nonneuropathic treatments.
In attempts to identify genes relevant to CIPN, several genomewide association studies (GWAS) have been conducted with the identification of SNP in FGD4 (9), EPHA5, and XKR4 (10) associated with the risk of paclitaxel-induced sensory peripheral neuropathy. Because it is challenging to replicate large, wellcontrolled clinical trials to evaluate pharmacogenomics markers of toxicity (11, 12) , we developed an integrative approach combining clinical studies and cell-based models enabling variant identification and followed with functional validation of the findings to help elucidate underlying mechanisms and pathways (13) . This method has found utility for paclitaxel-induced peripheral neuropathy in individuals of European descent and capecitabine-induced hand-foot syndrome (14, 15) .
Although paclitaxel is used globally, large clinical GWAS studies of paclitaxel-induced sensory peripheral neuropathy have been performed primarily in European patients (9, 10, 14, 16) . However, pharmacoethnicity has been recognized as an important factor in chemotherapeutic response and toxicity (17) . In this report, we compare genetic variants identified in a GWAS of sensitivity of lymphoblastoid cell lines derived from individuals of Asian, European, and African ancestry to variants identified in an Asian patient GWAS of paclitaxel neuropathy. In addition to analyzing SNPs, we identified significant genes through expression quantitative trait loci (eQTL) data (18) and functionally validate a target gene using human-induced pluripotent stem cell (iPSC)-derived neurons.
Materials and Methods

Cytotoxicity assays
HapMap lymphoblastoid cell lines (LCL) derived from Japanese individuals residing in Tokyo, Japan (HAPMAPPT02/05, JPT, n ¼ 57) and a set derived from Han Chinese residing in Beijing, China (HAPMAPPT02/05, CHB, n ¼ 59), purchased from the Coriell Cell Repositories (Camden), were treated with increasing concentrations (0, 6.25, 12.5, 25, 50, and 100nM) of paclitaxel (Sigma-Aldrich, St. Louis, MO, USA). Cytotoxicity was determined using an AlamarBlue (Invitrogen, Life Technologies Inc.) cellular growth inhibition assay as described previously (19) . Mean area under the paclitaxel concentration-cell survival percentage curve (AUC) was determined by at least six replicates from two independent experiments and used as the phenotype in the GWAS. AUC values for each cell line were log 2 -transformed before statistical analysis to form an approximately normal distribution. Paclitaxel cytotoxicity data of CEU (n ¼ 77), YRI (n ¼ 87), and ASW (n ¼ 83) are previously published (19) . For each population, a linear regression was calculated to determine the correlation between the AUC for each replicate; the correlation for CEU, YRI, ASW, CHB, and JPT was 0.83, 0.86, 0.81, 0.83, and 0.82, respectively.
Authentication of cell lines
The PAAR Cell Core routinely checks the identity of LCLs by genotyping 47 
Translational Relevance
Chemotherapy-induced peripheral neuropathy (CIPN) causes a significant symptom burden because many patients that undergo adjuvant treatment are long-term survivors. Moreover, CIPN can lead to dose reduction of the chemotherapeutic agent or possible cessation of treatment. This may have an adverse impact on cancer treatment and disease outcomes. In this study, we have used a genome-wide approach in a clinical and preclinical setting to identify genetic variants associated with peripheral neuropathy in Asians. The findings can be used in a clinical setting to dose reduce patients at risk or alter therapy to avoid this devastating side effect. In addition, an improved understanding of the pathophysiology of paclitaxel-induced neuropathy in and across populations will assist in the development of future neuroprotective agents and in the design of novel therapies with improved toxicity profiles.
paclitaxel-induced sensory peripheral neuropathy (PIPN), 121 patients revealed no neuropathy, and the remaining 38 individuals had grade 1 neuropathy. For GWAS, we used 24 patients who developed ! grade 2 PIPN (cases), and compared them with 121 patients who did not show neuropathy (controls). The patient characteristics are described in Supplementary Table S1 . The grade of toxicity was classified in accordance with the US National Cancer Institute's Common Toxicity Criteria version 2.0. All participants provided written informed consent. This project was approved by the Institutional Review Board in the Institute of Medical Science, the University of Tokyo, and RIKEN Center for Genomic Medicine. Sample quality control was carried out by methods, including identity-by-state to evaluate cryptic relatedness for each sample, and population stratification by the use of principal component (PC) analysis to exclude genetically heterogeneous samples from further analysis. Then, our standard SNP quality control was carried out by excluding SNPs deviating from the HardyWeinberg equilibrium (P 10 À6 ), nonpolymorphic SNPs, SNPs with a call rate of <0.99, and those on the X chromosome. We performed a genome-wide case/control allelic association study using the Fisher exact test.
LCL/patient comparison
We used the SCAN database to determine which of the top SNPs significantly associated with paclitaxel-induced cytotoxicity in ASN (P < 10 À6 ) were located in or near (within 2 kb) gene transcripts (24, 25) . We also used the eQTL Browser (http://eqtl.uchicago.edu/Home.html) and GTEx Portal (http://www.gtexportal.org/home/) to detect whether SNPs genotyped in 1000 Genomes were eQTLs in LCLs and other tissues. The previous genomic studies using LCLs showed that Japanese and Han Chinese have similar genetic structure, but cluster separately from European and African-American individuals in PCs analysis (26) . We used Sherlock, the computational algorithm that matches patterns of GWAS results with independent eQTL data to detect significant genes associated with the cytotoxicity and neuropathy phenotypes (18) . We used the public HapMap CEU eQTL dataset (27) contained in Sherlock for gene association testing. Among the genes associated with each phenotype (P < 0.05) through Sherlock (18), the LCL/patient overlap genes were prioritized for functional analysis. Results were also compared with the published clinical GWAS of 855 genetic Europeans with breast cancer from CALGB40101, in which a dose-to-event analysis was conducted with an event defined as paclitaxel-induced sensory peripheral neuropathy ! grade 2 (9).
Functional studies in iPSC-derived neurons
Human iPSC-derived cortical neurons, termed iCell Neurons (Cellular Dynamics International), were used for functional validation of the candidate genes. These cells have been previously used to model chemotherapy-induced neuropathy (28, 29) .
RNA-Seq. RNA isolation from iPSC-derived cortical neurons was performed after removal of media and addition of 50 mL Qiazol per well plate for 5 minutes at room temperature to lyse cells. After vigorously pipetting each well several times, samples were collected and stored for further processing at À70 C. RNA was purified using the Ambion RNA protocol (15596026.PPS), only substituting Qiazol as the lysing reagent after consulting with the company. The final pellets were resuspended in 50 mL RNAase-free water dissolved at 55 C for 10 minutes, aliquoted and stored at À70 C. Nucleic acids quantification was performed using the Qubit dye for RNA kits (Molecular Probes, Life Technologies), as per the manufacturer's specifications. RNA (1 mg) from each time point was submitted to the University of Chicago Genomics Core. RNA quality was checked on the Agilent Bio-analyzer 2100. RNA-SEQ libraries were generated in the core using Illumina RS-122-2101 TruSeq Stranded mRNA LT Libraries and the final libraries checked again on the Agilent bio-analyzer 2100, which was followed by sequencing on the Illumina HiSeq2500. The raw sequencing reads were processed and analyzed using the RNA-Seq pipeline in the Galaxy Project (30) . Briefly, the raw reads were mapped to the human genome reference (hg19) using TopHat2 (version 2.06; ref. 31) , which aligns RNA-Seq reads to the human genomes using the ultra high-throughput short read aligner Bowtie2 (32) . Cufflinks (version 0.0.7; ref. 33 ) was then used to quantify and quantile normalize the expression levels of the assembled transcripts.
siRNA knockdown studies. iCell Neurons (1.33 Â 10 4 ) were seeded with 3.3 mg/mL laminin (Sigma-Aldrich) in iCell Neuron complete maintenance media onto poly-D-lysine coated 96-well Greiner Bio-One plates (Monroe) according to the manufacture's recommendations. Dharmacon Accell technology (GE Dharmacon) was applied at 4 hours after plating using 1 mmol/L each human siAIPL1, siPTPMT1, siBCR, or siDDX54 SMARTpool or the nontargeting control (NTC). Twenty-four hours later cells were either collected for real-time reverse transcription PCR (RT-PCR) or an exchange of transfection media with paclitaxel at a dose range of 0.001 to 10 mmol/L or 0.17% DMSO vehicle control. After 24 or 48 hours, the drug was removed and cells were stained with 1 mg/mL Hoechst 33342 (Sigma-Aldrich) and 2 mg/mL Calcein AM in dPBS (Molecular Probes, Life Technologies Inc.). Image analysis was performed on the ImageXpress Micro imaging system (Molecular Devices, LLC) at the University of Chicago Cellular Screening Center. Individual cell measurements of neurite outgrowth, including mean/median/maximum process length, total neurite outgrowth (sum of the length of all processes), number of processes, number of branches, cell body area, mean outgrowth intensity and straightness were analyzed using the MetaXpress software Neurite Outgrowth Application Module. Each experiment was replicated three times and the difference in the relative neurite outgrowth for each siRNA treatment was compared with NTC and tested for significance by two-way ANOVA analysis.
Cells for RT-PCR from 2 wells for each experiment were collected at 24 and 48 hours posttransfection using Cells to CT (Life Technologies) as recommended by the manufacturer. Two independent reverse transcription reactions were performed, and the efficiency of knockdown for AIPL1 (Hs04185077_m1), PTPMT1 (Hs00378514_m1), BCR (Hs01036532_m1), or DDX54 (Hs_00225320_m1; Life Technologies) for triplicate wells was determined using TaqMan fast chemistry on the Viia7 PCR machine (Life Technologies). A comparative DDC t analysis was used to determine the percentage knockdown of each gene by comparing the C t difference relative with the beta-2-microglobulin control (NM_004048.2) and normalizing to NTC.
Results
Paclitaxel-induced cytotoxicity in LCLs
HapMap LCLs were treated with increasing concentrations of paclitaxel and cellular growth inhibition was measured. The log 2 -transformed area under the survival curve (AUC) was used as the paclitaxel-induced cytotoxicity phenotype. To evaluate ethnic differences in mean log 2 AUC of paclitaxel, we compared results from LCLs derived from the Asian populations (JPT, n ¼ 57; CHB, n ¼ 59) with our previous data of three other HapMap LCL populations (CEU, n ¼ 77; YRI, n ¼ 87; ASW, n ¼ 83; ref. 19 ). The paclitaxel-induced log 2 -transformed cytotoxicity phenotype showed normal distributions in each population. Figure 1 illustrates the paclitaxel-induced cytotoxicity among 5 populations with no statistical differences among the populations observed. Figure 2 illustrates the Manhattan plot of paclitaxel-induced cytotoxicity in LCLs derived from the Asian populations (JPT and CHB). There were 248 SNPs associated with paclitaxel cytotoxicity in the ASN population at a suggestive significance of P < 10 À5 ;
Genome-wide association study in Asian LCLs
however, among them only one SNP (rs56763443) and two SNPs (rs8049617 and rs7598550) were significant in the CEU and YRI GWAS results at P < 0.05, respectively. Three of the most significant six SNPs in the ASN GWAS of paclitaxel-induced cytotoxicity were located near (within 2 kb) gene AIPL1 (aryl-hydrocarboninteracting protein-like 1). The three AIPL1 SNPs are in perfect LD (r 2 ¼ 1, D 0 ¼ 1 in ASN), and thus represent one signal. We evaluated whether any of these six SNPs were expression quantitative trait loci eQTLs with r 2 ! 0.8 in two distinct databases, University of Chicago database (http://eqtl.uchicago.edu/cgi-bin/ gbrowse/eqtl/) and GTEx Portal (http://www.gtexportal.org); however, they were not eQTLs in any tissues listed (generic genome browser version 1.68). We also downloaded the expression data collected from ASN LCLs in Stranger and colleagues (34) Table 1 illustrates these three SNPs trending toward significance in LCLs derived from individuals of Northern/Western Europe (CEU; P < 0.065-0.078), but there was no significance in African LCLs (YRI; P ¼ 0.305-0.355). Thus, the genetic variation near AIPL1 may contribute to paclitaxel-induced cytotoxicity particularly in Asians. Supplementary Table S2 lists 28 SNPs in or near AIPL1 and their association with sensory neuropathy in Asian patients; one SNP (rs7214517) has a P value of 0.028. The three LCL SNPs (rs56763443, rs8049617, and rs7598550) were not genotyped in the Asian study.
Functional validation of AIPL1 using human iPSC-derived neurons
The effects of AIPL1 expression on paclitaxel-induced neurotoxicity was assessed in neurons derived from iPSCs. To evaluate the effects of low AIPL1, expression on paclitaxel-induced neurotoxicity, we modulated the gene in neurons through transient siRNA transfection and verified with quantitative PCR (qPCR), a reduction of expression in AIPL1 to 62% and 14% relative to control at 24 and 48 hours posttransfection relative to NTC (Fig. 3A) . The modulation of expression of AIPL1 resulted in increased resistance of neurons to paclitaxel at 48 hours using two-way ANOVA analysis, as measured by significant increase in relative total outgrowth ( Fig. 3B ; P ¼ 0.017), mean process length ( Fig. 3C ; P ¼ 0.008), and relative number of processes ( Fig. 3D ; P ¼ 0.029). Median process length (P ¼ 0.005), max process length (P ¼ 0.011), phenotypes related to mean process length and mean outgrowth intensity, a phenotype related to thickening of the neurite outgrowths (P ¼ 0.0065) was also significantly mmol/L) were tested for differences between siAIPL1 and NTC by two-way ANOVA, including relative total neurite outgrowth (P ¼ 0.017; B), relative mean process length (P ¼ 0.008; C), and relative number of processes (P ¼ 0.029; D). Error bars, SEM from three experiments of >2,000 cells per dose. E, representative highcontent images comparing human iPSC-derived neurons upon siRNA knockdown of AIPL1 and NTC 48 hours after treatment with 0.01 mol/L paclitaxel. Images taken at Â10 magnification; scale bar, 100 mm. Figure 3E illustrates morphologic changes for NTC-and siAIPL1-treated cells for neurite outgrowth following 48 hours paclitaxel treatment of iPSC-derived neurons by high-content imaging.
GWAS in patient samples of paclitaxel-induced neuropathy
We performed GWAS of paclitaxel-induced neuropathy in 183 Asian cancer patients (Fig. 4A) . We identified four SNPs above a suggestive threshold of P < 10 À5 and no genome wide significant SNPs at P ¼ 5 Â 10 À8 . Gene-based tests are commonly used following traditional SNP-based analysis because they reduce multiple testing and provide genes as opposed to SNPs. Therefore, we evaluated LCL Asian GWAS (Fig. 2) , Asian cancer patient data (Fig. 4A) , and GWAS data from CALGB40101, a study of 855 Europeans evaluated for paclitaxel-induced neuropathy (9) Table S5) . Interestingly, PTPMT1 (protein tyrosine phosphatase, mitochondrial 1) overlapped all three analyses: Asian LCL cytotoxicity, Asian patient neuropathy, and European patient neuropathy at P < 0.05. Although we modulated gene expression of PTPMT1 in iCell neurons, resulting in 77% and 41% gene remaining after 24 and 48 hours, no significant difference was found in any of the neurite outgrowth phenotypes when compared with NTC (data not shown), indicating that some mechanism distinct from levels of gene expression may explain the role of PTPMT1 in paclitaxelinduced peripheral neuropathy. Alternatively, the effect of gene knockdown on other neuronal phenotypes such as electrical activity would not be captured in this system that is focused on morphologic changes.
Functional validation of BCR and DDX54 using human iPSC-derived neurons To prioritize the 32 Asian specific genes (Supplementary  Table S3 ), we evaluated both their gene level expression in Fig. S6 ). Breakpoint cluster region (Bcr) protein, highly expressed in iPSC-derived neurons, is enriched in neurons and involved in neural activities, and therefore was chosen for further studies (35) (36) (37) . We found that a change in expression to 62% and 67% at 24 and 48 hours compared with NTC (Fig. 5A) , resulting in a decrease in the relative total outgrowth (P ¼ 0.0097), number of processes (P ¼ 0.0298), max process length (P ¼ 0.0016), and number of branches (P ¼ 0.0003; Fig. 5B-D) after treatment with paclitaxel in three independent experiments. Ddx54 protein has been shown to play a critical role in central nervous system myelination, presumably in myelin sheath formation after the differentiation of oligodendrocytes (38) . DDX54 (DEAD-box RNA helicase) was modulated to 66% and 61% at 24 and 48 hours, but resulted in no significant changes in any neurite phenotype measured, including relative total outgrowth, number of processes, max process length, and number of branches.
Discussion
A comparison of paclitaxel-induced cytotoxicity in LCLs derived from patients of Asian, European, and African ancestry demonstrates no difference in cellular sensitivity to paclitaxel. Traditional GWAS reveals only a small fraction (3/248) SNPs suggestively significant in Asian LCLs for paclitaxel-induced cytotoxicity are also significant in either CEU or YRI LCLs with the most significant genetic variant associations unique within populations. The top intragenic SNPs in the ASN GWAS of paclitaxel-induced cytotoxicity were located near AIPL1 gene. Upon knockdown of AIPL1 in human iPSC-derived neurons, decreased sensitivity to paclitaxel as measured by neurite outgrowth phenotypes was observed. Using a gene-based approach, a gene identified as Asian specific (overlapped in Asian LCLs and Asian clinical cohort of neuropathy) BCR (breakpoint cluster region), was validated using iPSC-derived neurons with knockdown corresponding to increased sensitivity to paclitaxel-induced damage to neurons. The same approach identified PTPMT1 associated with paclitaxel-induced cytotoxicity in Asian LCLs, as well as Asian and European paclitaxel-induced peripheral neuropathy clinical cohorts. By integrating gene-based analyses from clinical studies of paclitaxel-induced neuropathy in Asian and European patients with LCL results, population specific, and across population target genes were identified.
The HapMap LCLs are advantageous for evaluating pharmacogenomics of anticancer agents because these samples have publicly available genotypes (39, 40) and sequencing data (20) for GWAS. The samples also have gene expression (41) , miRNA (42) , modified cytosine (43) , and protein data (44) that allow for the elucidation of potential function of the genetic variants associated with pharmacologic phenotypes. Our observation of a lack of population difference in paclitaxel-induced cytotoxicity is in contrast with population differences observed for platinating agents (45) and antimetabolites (46) . In part, these population differences in drug sensitivity may be explained by population differences in gene expression (41) . The role of gene expression in population differences in chemotherapeutic cytotoxicity is supported by the observation that pharmacologic SNPs for several different chemotherapeutic agents (etoposide, daunorubicin, cisplatin, carboplatin, cytarabine, and capecitabine) are enriched in eQTLs or SNPs associated with gene expression (25) . In contrast, pharmacologic SNPs associated with paclitaxel are not enriched in eQTLs; however, enrichment in protein quantitative trait loci has been observed (47). These differences may be due to differences in mechanism of action of paclitaxel, a microtubule stabilizer compared with the other cytotoxic agents that target DNA. In our Asian patient dataset, it appears that peripheral neuropathy is more common in females than males (males: 1 case/33 controls; females: 23 cases/88 controls); however, this gender difference is likely confounded by differences in cumulative dose, treatment schedule or age of the patients. Evidence suggests that age, race, and comorbid conditions, such as diabetes, and cumulative dose of drug administered may be associated with an increased risk of developing neuropathy (48) .
In efforts to decrease multiple tests and identify genes instead of SNPs, we chose to utilize a gene-based approach to detect clinically significant genes with multiple trans eQTLs with moderate associations, which cannot be identified from the GWAS alone (18) . We used Sherlock to compare genes significant in two patient studies of paclitaxel-induced neuropathy (855 European and 183 Japanese) and the LCL data we generated in the Asian populations. According to the gene-based test, 10 genes, including PTPMT1, were found to overlap between Asians and Europeans along with hundreds of candidate gene associations that were unique to each population. At this threshold, PTPMT1 was revealed as a common target of paclitaxel-induced sensory peripheral neuropathy among populations. PTPMT1 is anchored in the inner mitochondrial membrane and is required for mitochondrial integrity and oxidative respiration (49) . Because its ablation increased apoptosis in cancer cell lines and decreased differentiation and proliferation, but not survival in embryonic stem cells, its function may be cell-type specific in the regulation of cell growth and survival (50) . Thus, PTPMT1 in peripheral nerve mitochondria may play a critical role in paclitaxel-induced neurotoxicity across populations and is worth further studies. Our data indicate that expression knockdown PTPMT1 in iPSCderived neurons did not alter sensitivity to paclitaxel as measured by morphologic changes in neuronal outgrowths; however, it is possible that the gene is important in electrical activity or other measures of neuronal damage.
Through LCL GWAS of paclitaxel-induced cytotoxicity, SNPs in AIPL1 were implicated as the most significant intragenic SNPs in the Asian LCLs. In evaluating SNPs within or close to AIPL1, rs7214517 was associated with Asian patient peripheral neuropathy (P ¼ 0.028). AIPL1 expressed in rod and cone photoreceptors has a critical role in cell viability, and gene defects in AIPL1 cause heterogeneous degenerations of the human retina, such as retinitis pigmentosa (51) . Interestingly, this disease is related to NARP syndrome (neuropathy, ataxia, and retinitis pigmentosa), which is an inherited condition chiefly affecting nervous systems due to mitochondrial DNA dysfunction in creating adenosine triphosphate (52) . Its worldwide prevalence is unknown and it remains unclear how this disruption in mitochondrial energy production leads to muscle weakness, vision loss and the other specific features of NARP syndrome. Kirschman and colleagues (53) also found that transgenic expression of AIPL1 restored rod morphology and the rod-derived electroretinogram response in Aipl À/À mice, implicating a neuron component for this gene. Mitochondrial dysfunction has been implicated as a mechanism for neurotoxicity of paclitaxel (54) and our results demonstrated that decreased expression of AIPL1 significantly decreased sensitivity of neurons to paclitaxel; hence, there could be a cell-type-specific function of AIPL1 in a mitochondrial component in peripheral neurons and AIPL1 could be a potential therapeutic target of paclitaxel-induced sensory peripheral neuropathy especially in Asians.
We identified a set of 32 Asian specific genes that overlapped in the Asian LCL and Asian patient datasets. One of those genes, BCR, was functionally validated in the iPSC-derived neuronal model with increased sensitivity of neurons to paclitaxel upon knockdown of the gene. Bcr has been shown in rat PC12 cells to cooperate with Fes to activate Rho family GTPases as part of a novel pathway regulating neurite extension (55) . Furthermore, Huntington's-associated protein, 1A interacts with Bcr on microtubules to regulate neuronal differentiation (56) . Increasingly, Bcr is emerging as an important regulator of excitatory synapse receptor expression and development. Our data indicate that BCR contributes to the protection of neurons from paclitaxel-induced damage as measured by several neuronal phenotypes, including total outgrowth of neurites.
Although CIPN is a common, potentially severe and doselimiting adverse effect of many commonly used cancer therapeutics, including paclitaxel, there are no effective genetic markers or treatment for this side effect (4, 7, 8) . Therefore, to identify genetic variants and genes associated with CIPN, several large clinical GWAS have been conducted and revealed a few promising associations (9, 10, 14) . However, there are some considerable issues in clinical GWAS of CIPN, including (i) lack of replication studies; (ii) pharmacogenomics underlying ethnic specificity; and (iii) lack of appropriate models to functionally validate important GWAS results. Therefore, combining cell-based data with multiple clinical genome-wide association studies, as done in this study, is a way to identify the most promising genes. Furthermore, we utilized a novel technology, human iPSCderived neurons for gene functional validation. The elucidation of variants specific to the Asian population may be helpful in developing personalized cancer treatments.
